Drug master file system
This article was originally published in The Tan Sheet
Executive Summary
FDA is reopening, until June 3, the comment period on a Jan. 31 public workshop related to possible improvements in the drug master file system, particularly Type II DMFs drug substances and intermediates. The agency said it is extending the original comment period by 60 days at the request of the International Pharmaceutical Excipients Council